Orion Biotechnology featured on BestStock.com
August 29, 2023
You can find the investment blog – BestStocks.com – and their take on the potential of Orion’s technology in a recently published article here.
News
Orion Biotechnology Completes Discovery of First-in-Class Molecule Against Undrugged GPCR Target in Four Months
July 18, 2023
Ottawa, Canada, July 18, 2023 (GLOBE NEWSWIRE) — Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs), today announced that it has
Orion Biotechnology Presenting at the 2nd GPCR-Targeted Drug Discovery Summit in Boston
February 24, 2023
Ottawa, Canada, Feb. 16, 2023 (GLOBE NEWSWIRE) — Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs), today announced that it will
Orion Biotechnology Publishes Whitepaper Highlighting the Importance and Challenges in Unlocking “Undruggable” GPCRs
February 24, 2023
Ottawa, Canada, Feb. 02, 2023 (GLOBE NEWSWIRE) — Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs), today announced that it has
Orion Biotechnology Shares In Vivo Efficacy Data on its Latest Best-in-Class Drug Candidate
February 24, 2023
Ottawa, Canada, Dec. 01, 2022 (GLOBE NEWSWIRE) — Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs), today announced that it has
Orion Biotechnology to Attend the LSX Investival Showcase & Jefferies Healthcare Conference
February 24, 2023
Ottawa, Ontario, Canada, Nov. 10, 2022 (GLOBE NEWSWIRE) — Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs), today announced that it
Global Headquarters
343 Preston Street
11th floor,
Ottawa, On K1S 1N4
CANADA
+1 343.291.1032
Switzerland
Campus Biotech
Innovation Park
Avenue de Sécheron 15
1202 Genève
SWITZERLAND
Poland
Orion Biotechnology
Life Science Park
UI Bobrzyńskiego 14
30-348 Krakôw
POLAND
